Availability of Transgene's 2024 Universal Registration Document (URD)
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers -- AMF) on April 10, 2025, under number D.25-0243.
This document, available on the AMF's website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene's website (www.transgene.fr)
It includes the following documents:
-- the Annual Financial Report;
-- the Board of Directors' Corporate Governance Report;
-- the Statutory Auditors' Reports;
-- information on the Company's share capital, including the share buyback
program;
-- information on the Statutory Auditors' fees.
The Universal Registration Document also includes information on the Company's Environmental, Social and Governance $(ESG)$ factors.
Attachment
-- 20250410_Transgene_publication_URD_2024_EN
(END) Dow Jones Newswires
April 10, 2025 14:15 ET (18:15 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.